{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:55:09Z","timestamp":1795211709831,"version":"4.10.3"},"reference-count":112,"publisher":"American Chemical Society (ACS)","issue":"23","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fragment-based drug discovery (FBDD) has led to dozens of clinical compounds, including eight approved drugs. For the past decade, we have published an annual review of successful fragment-to-lead (F2L) medicinal chemistry programs. This Perspective marks the tenth in the series. We analyze the 18 F2L case studies from 2024 and put them in the context of the larger set of 233 examples dating back to 2015. We hope that the lessons herein will both inform and inspire researchers to discover the next generation of drugs.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c02894","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T02:33:16Z","timestamp":1764124396000},"page":"24830-24847","source":"Crossref","is-referenced-by-count":25,"title":["Fragment-to-Lead\nMedicinal Chemistry Publications\nin 2024: A Tenth Annual Perspective"],"prefix":"10.1021","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5479-1050","authenticated-orcid":true,"given":"David G.","family":"Twigg","sequence":"first","affiliation":[{"name":"Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road , ,","place":["Cambridge, U.K., CB4 0QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Arai","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road , ,","place":["Cambridge, U.K., CB4 0QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9366-6770","authenticated-orcid":true,"given":"Michelle R.","family":"Arkin","sequence":"additional","affiliation":[{"name":"University of California San Francisco (UCSF) , , , ,","place":["San Francisco, California, United States, 94158"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-4159","authenticated-orcid":true,"given":"Daniel A.","family":"Erlanson","sequence":"additional","affiliation":[{"name":"Frontier Medicines , 151 Oyster Point Blvd. , , ,","place":["South San Francisco, California, United States, 94080"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1969-0238","authenticated-orcid":true,"given":"Iwan J. P.","family":"de Esch","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Amsterdam , , De Boelelaan 1108 , ,","place":["Amsterdam, The Netherlands, 1081 HZ"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-1673","authenticated-orcid":true,"given":"Barbara","family":"Farkas\u030c","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road , ,","place":["Cambridge, U.K., CB4 0QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-6192","authenticated-orcid":true,"given":"Stephen W.","family":"Fesik","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine , , , ,","place":["Nashville, Tennessee, United States, 37232-0146"]},{"name":"Vanderbilt University , , , ,","place":["Nashville, Tennessee, United States, 37232-0142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-3305","authenticated-orcid":true,"given":"Wolfgang","family":"Jahnke","sequence":"additional","affiliation":[{"name":"Discovery Sciences , , ,","place":["Basel, Switzerland, 4002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8618-9729","authenticated-orcid":true,"given":"Christopher N.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road , ,","place":["Cambridge, U.K., CB4 0QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Discovery Sciences , , ,","place":["Basel, Switzerland, 4002"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"1","key":"2026072715450560000_cit1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1042\/BST20190694","article-title":"Fragments:\nwhere are we now?","volume":"48","author":"Osborne","year":"2020","journal-title":"Biochem. Soc. Trans."},{"issue":"5","key":"2026072715450560000_cit2","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1021\/acs.jmedchem.5c00424","article-title":"Fragment-Based Drug\nDesign: From Then until Now, and Toward the Future","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"5292","key":"2026072715450560000_cit3","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1126\/science.274.5292.1531","article-title":"Discovering high-affinity\nligands for proteins: SAR by NMR","volume":"274","author":"Shuker","year":"1996","journal-title":"Science"},{"key":"2026072715450560000_cit4","unstructured":"Practical\nFragments. http:\/\/practicalfragments.blogspot.com\/ (accessed March 05, 2025)."},{"issue":"1","key":"2026072715450560000_cit5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1021\/acs.jmedchem.6b01123","article-title":"Fragment-to-Lead\nMedicinal Chemistry Publications in 2015","volume":"60","author":"Johnson","year":"2017","journal-title":"J.\nMed. Chem."},{"issue":"5","key":"2026072715450560000_cit6","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1021\/acs.jmedchem.7b01298","article-title":"Fragment-to-Lead Medicinal Chemistry Publications in\n2016","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026072715450560000_cit7","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1021\/acs.jmedchem.8b01472","article-title":"Fragment-to-Lead\nMedicinal Chemistry Publications in 2017","volume":"62","author":"Mortenson","year":"2019","journal-title":"J.\nMed. Chem."},{"issue":"9","key":"2026072715450560000_cit8","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1021\/acs.jmedchem.9b01581","article-title":"Fragment-to-Lead\nMedicinal Chemistry Publications in 2018","volume":"63","author":"Erlanson","year":"2020","journal-title":"J.\nMed. Chem."},{"issue":"24","key":"2026072715450560000_cit9","doi-asserted-by":"publisher","first-page":"15494","DOI":"10.1021\/acs.jmedchem.0c01608","article-title":"Fragment-to-Lead Medicinal\nChemistry\nPublications in 2019","volume":"63","author":"Jahnke","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026072715450560000_cit10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/acs.jmedchem.1c01803","article-title":"Fragment-to-Lead Medicinal Chemistry Publications in 2020","volume":"65","author":"de Esch","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026072715450560000_cit11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/acs.jmedchem.2c01827","article-title":"Fragment-to-Lead Medicinal\nChemistry Publications in 2021","volume":"66","author":"Walsh","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026072715450560000_cit12","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1021\/acs.jmedchem.3c02070","article-title":"Fragment-to-Lead Medicinal Chemistry Publications in\n2022","volume":"67","author":"Woodhead","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026072715450560000_cit13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1021\/acs.jmedchem.4c02593","article-title":"Fragment-to-Lead Medicinal Chemistry\nPublications in 2023","volume":"68","author":"Holvey","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026072715450560000_cit14","unstructured":"Leo, A. W. D.\n          \n          CLOGP\nReference Manual, Daylight version 4.9; Daylight\nChemical Information Systems, Inc: Laguna Niguel, CA, 2011. http:\/\/www.daylight.com\/dayhtml\/doc\/clogp\/."},{"key":"2026072715450560000_cit15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116499","article-title":"Design, synthesis and biological evaluation\nof 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine\nderivatives as Mnk1\/2 inhibitors","volume":"272","author":"Xing","year":"2024","journal-title":"Eur. J. Med.\nChem."},{"issue":"18","key":"2026072715450560000_cit16","doi-asserted-by":"publisher","first-page":"13719","DOI":"10.1021\/acs.jmedchem.1c01084","article-title":"Optimization of 4,6-Disubstituted\nPyrido[3,2-d]pyrimidines as Dual\nMNK\/PIM Inhibitors to Inhibit Leukemia Cell Growth","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026072715450560000_cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116292","article-title":"Imidazo[1,2-b]pyridazines as inhibitors\nof DYRK kinases","volume":"269","author":"Henderson","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"2026072715450560000_cit18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ejmech.2016.09.064","article-title":"Exploration of the\nimidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor","volume":"125","author":"Bendjeddou","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"2026072715450560000_cit19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib\n(RLY-4008), a highly selective irreversible small-molecule inhibitor\nof FGFR2","volume":"121","author":"Scho\u0308nherr","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"2026072715450560000_cit20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1021\/acs.jmedchem.3c01439","article-title":"Fragment Merging, Growing, and Linking Identify\nNew Trypanothione Reductase Inhibitors for Leishmaniasis","volume":"67","author":"Exertier","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026072715450560000_cit21","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.900882","article-title":"Innovative Approach\nfor a Classic Target: Fragment Screening on Trypanothione Reductase\nReveals New Opportunities for Drug Design","volume":"9","author":"Fiorillo","year":"2022","journal-title":"Front.\nMol. Biosci."},{"issue":"13","key":"2026072715450560000_cit22","doi-asserted-by":"publisher","first-page":"11168","DOI":"10.1021\/acs.jmedchem.4c00702","article-title":"Fragment-Based Discovery of a Series of Allosteric-Binding\nSite Modulators of \u03b2-Glucocerebrosidase","volume":"67","author":"Palmer","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026072715450560000_cit23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1021\/acsmedchemlett.3c00453","article-title":"Fragment-Based Discovery of Novel MUS81 Inhibitors","volume":"15","author":"Collie","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"2026072715450560000_cit24","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1021\/acs.jmedchem.3c02118","article-title":"Fragment-Based Discovery of Allosteric Inhibitors\nof SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)","volume":"67","author":"Day","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026072715450560000_cit25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1021\/acsmedchemlett.3c00543","article-title":"Discovery of Alternative\nBinding Poses through Fragment-Based\nIdentification of DHODH Inhibitors","volume":"15","author":"DeRatt","year":"2024","journal-title":"ACS Med.\nChem. Lett."},{"issue":"19","key":"2026072715450560000_cit26","doi-asserted-by":"publisher","first-page":"17363","DOI":"10.1021\/acs.jmedchem.4c01262","article-title":"Development of Fragment-Based Inhibitors\nof\nthe Bacterial Deacetylase LpxC with Low Nanomolar Activity","volume":"67","author":"Mielniczuk","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026072715450560000_cit27","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.bmc.2013.12.057","article-title":"Synthesis,\nbiological\nevaluation and molecular docking studies of benzyloxyacetohydroxamic\nacids as LpxC inhibitors","volume":"22","author":"Szermerski","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"2026072715450560000_cit28","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.bmc.2016.01.029","article-title":"Synthesis and biological evaluation\nof enantiomerically pure glyceric acid derivatives as LpxC inhibitors","volume":"24","author":"Tangherlini","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"2026072715450560000_cit29","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1021\/acs.jmedchem.4c00149","article-title":"Development of Novel Phosphonodifluoromethyl-Containing\nPhosphotyrosine Mimetics and a First-In-Class, Potent, Selective,\nand Bioavailable Inhibitor of Human CDC14 Phosphatases","volume":"67","author":"Dong","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026072715450560000_cit30","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1021\/acs.jmedchem.3c01860","article-title":"Development of a Series of Pyrrolopyridone\nMAT2A Inhibitors","volume":"67","author":"Atkinson","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026072715450560000_cit31","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1021\/acsmedchemlett.4c00117","article-title":"Discovery of Broad-Spectrum Herpes Antiviral Oxazolidinone\nAmide Derivatives and Their Structure-Activity Relationships","volume":"15","author":"Plotkin","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"2026072715450560000_cit32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116991","article-title":"Structure-guided inhibitor\ndesign targeting CntL provides the first\nchemical validation of the staphylopine metallophore system in bacterial\nmetal acquisition","volume":"280","author":"Luo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"2026072715450560000_cit33","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202002287RR","article-title":"Structural\ninsights into the ligand recognition and catalysis of\nthe key aminobutanoyltransferase CntL in staphylopine biosynthesis","volume":"35","author":"Luo","year":"2021","journal-title":"FASEB J."},{"issue":"1","key":"2026072715450560000_cit34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54356-1","article-title":"Integrating fragment-based screening with targeted\nprotein degradation and genetic rescue to explore eIF4E function","volume":"15","author":"Sharp","year":"2024","journal-title":"Nat. Commun."},{"key":"2026072715450560000_cit35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129546","article-title":"Discovery of PFI-6,\na small-molecule chemical probe for the YEATS domain of MLLT1 and\nMLLT3","volume":"98","author":"Raux","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8013","key":"2026072715450560000_cit36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41586-024-07387-z","article-title":"Discovery\nof potent small-molecule inhibitors\nof lipoprotein(a) formation","volume":"629","author":"Diaz","year":"2024","journal-title":"Nature"},{"issue":"17","key":"2026072715450560000_cit37","doi-asserted-by":"publisher","first-page":"15521","DOI":"10.1021\/acs.jmedchem.4c01165","article-title":"Selective Aurora A-TPX2\nInteraction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic\nAgents","volume":"67","author":"Stockwell","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026072715450560000_cit38","doi-asserted-by":"publisher","DOI":"10.1038\/s42004-024-01224-0","article-title":"Development of Nurr1\nagonists from amodiaquine by scaffold hopping and fragment growing","volume":"7","author":"Sai","year":"2024","journal-title":"Commun. Chem."},{"issue":"5","key":"2026072715450560000_cit39","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1021\/acs.jmedchem.0c01779","article-title":"Fragment-like\nChloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and\nElucidate Activation Mechanisms","volume":"64","author":"Willems","year":"2021","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026072715450560000_cit40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric\nfor lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discovery Today"},{"issue":"11","key":"2026072715450560000_cit41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making\nin medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"15","key":"2026072715450560000_cit42","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1016\/j.bmcl.2009.05.062","article-title":"Rapid assessment\nof a novel series of selective CB(2) agonists using parallel synthesis\nprotocols: A Lipophilic Efficiency (LipE) analysis","volume":"19","author":"Ryckmans","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"2026072715450560000_cit43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10822-011-9435-z","article-title":"Assessing the lipophilicity\nof fragments and early\nhits","volume":"25","author":"Mortenson","year":"2011","journal-title":"J. Comput.-Aided Mol. Des."},{"issue":"8011","key":"2026072715450560000_cit44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41586-024-07318-y","article-title":"Chemoproteomic\ndiscovery of a covalent allosteric\ninhibitor of WRN helicase","volume":"629","author":"Baltgalvis","year":"2024","journal-title":"Nature"},{"issue":"8","key":"2026072715450560000_cit45","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1158\/2159-8290.CD-24-0052","article-title":"Novel\nWRN Helicase Inhibitors Selectively Target Microsatellite-Unstable\nCancer Cells","volume":"14","author":"Picco","year":"2024","journal-title":"Cancer Discovery"},{"issue":"18","key":"2026072715450560000_cit46","doi-asserted-by":"publisher","first-page":"16455","DOI":"10.1021\/acs.jmedchem.4c01288","article-title":"Structure-Based Optimization\nof a Series of Covalent, Cell Active Bfl-1 Inhibitors","volume":"67","author":"Lucas","year":"2024","journal-title":"J. Med. Chem."},{"issue":"24","key":"2026072715450560000_cit47","doi-asserted-by":"publisher","first-page":"22055","DOI":"10.1021\/acs.jmedchem.4c01995","article-title":"Structure-Based\nDiscovery\nof a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors","volume":"67","author":"Palisse","year":"2024","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026072715450560000_cit48","doi-asserted-by":"publisher","first-page":"11209","DOI":"10.1021\/acs.jmedchem.4c00781","article-title":"Design\nof a Lead-Like Cysteine-Targeting Covalent Library\nand the Identification of Hits to Cys55 of Bfl-1","volume":"67","author":"Lucas","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026072715450560000_cit49","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjsbx.2024.100100","article-title":"Optimizing NMR fragment-based\ndrug screening for membrane protein targets","volume":"9","author":"Li","year":"2024","journal-title":"J. Struct. Biol.: X"},{"issue":"7","key":"2026072715450560000_cit50","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1021\/jacsau.4c00427","article-title":"Ligandability at the Membrane Interface\nof GPx4 Revealed\nthrough a Reverse Micelle Fragment Screening Platform","volume":"4","author":"Labrecque","year":"2024","journal-title":"JACS Au"},{"issue":"12","key":"2026072715450560000_cit51","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.3390\/molecules29122814","article-title":"Ligand Screening\nof Membrane Proteins\nEmbedded in Nanodiscs: How to Manage Non-Specific Interactions in\nWeak Affinity Chromatography?","volume":"29","author":"Vidal","year":"2024","journal-title":"Molecules"},{"issue":"2","key":"2026072715450560000_cit52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1107\/S2059798324000329","article-title":"Fragment-based\nscreening\ntargeting an open form of the SARS-CoV-2 main protease binding pocket","volume":"80","author":"Huang","year":"2024","journal-title":"Acta Crystallogr., Sect. D: Struct. Biol."},{"issue":"2","key":"2026072715450560000_cit53","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acschembio.3c00720","article-title":"Targeting\nthe Main Protease (Mpro, nsp5) by Growth\nof Fragment Scaffolds Exploiting Structure-Based Methodologies","volume":"19","author":"Altincekic","year":"2024","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"2026072715450560000_cit54","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1021\/acsmedchemlett.4c00238","article-title":"Fragment-Based Screen\nof SARS-CoV-2 Papain-like Protease (PLpro)","volume":"15","author":"Taylor","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"2026072715450560000_cit55","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2024.1379518","article-title":"Fragment-based drug\ndiscovery for disorders of the central nervous system: designing better\ndrugs piece by piece","volume":"12","author":"Chan","year":"2024","journal-title":"Front. Chem."},{"issue":"1","key":"2026072715450560000_cit56","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06584-w","article-title":"A ligand\ndiscovery toolbox for the WWE domain family of human E3\nligases","volume":"7","author":"Mu\u0308nzker","year":"2024","journal-title":"Commun. Biol."},{"issue":"3","key":"2026072715450560000_cit57","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4904","article-title":"Identification of small-molecule binding sites of a\nubiquitin-conjugating enzyme- UBE2T through fragment-based screening","volume":"33","author":"Loh","year":"2024","journal-title":"Protein Sci."},{"key":"2026072715450560000_cit58","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2024.117539","article-title":"Review of the impact of fragment-based drug design\non PROTAC degrader discovery","volume":"171","author":"Chen","year":"2024","journal-title":"TrAC, Trends Anal.\nChem."},{"issue":"12","key":"2026072715450560000_cit59","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1080\/17460441.2024.2415310","article-title":"Fragment-based approaches\nto discover ligands for tumor-specific E3 ligases","volume":"19","author":"Yim","year":"2024","journal-title":"Expert Opin. Drug Discovery"},{"issue":"4","key":"2026072715450560000_cit60","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/17460441.2024.2306845","article-title":"Molecular\nglue degraders: exciting opportunities for\nnovel drug discovery","volume":"19","author":"Lemaitre","year":"2024","journal-title":"Expert Opin. Drug Discovery"},{"issue":"9","key":"2026072715450560000_cit61","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1021\/acschembio.4c00077","article-title":"Identification and Characterization of Novel Small-Molecule\nEnhancers of the CUL3LZTR1 E3 Ligase KRAS Complex","volume":"19","author":"Piech","year":"2024","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"2026072715450560000_cit62","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202300636","article-title":"Discovery of 14\u20133-3 PPI Stabilizers\nby Extension of an Amidine-Substituted Thiophene Fragment","volume":"25","author":"Wu","year":"2024","journal-title":"ChemBioChem"},{"issue":"17","key":"2026072715450560000_cit63","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1021\/acs.biochem.4c00248","article-title":"Fragment-Based\nInterrogation\nof the 14\u20133-3\/TAZ. Protein-Protein Interaction","volume":"63","author":"Andlovic","year":"2024","journal-title":"Biochemistry"},{"issue":"14","key":"2026072715450560000_cit64","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202400214","article-title":"Fourteen-three-three Protein-Protein\nInteractions:\nFrom Mechanistic Understanding to Their Small-Molecule Stabilization","volume":"25","author":"Somsen","year":"2024","journal-title":"ChemBioChem"},{"issue":"1","key":"2026072715450560000_cit65","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1039\/D3MD00322A","article-title":"NMR 1H,19F-based screening of the\nfour stem-looped structure 5_SL1-SL4 located in the 5\u2032-untranslated\nregion of SARS-CoV 2 RNA","volume":"15","author":"Hymon","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"26","key":"2026072715450560000_cit66","doi-asserted-by":"publisher","first-page":"17974","DOI":"10.1021\/jacs.4c04000","article-title":"Rapid Protein-Ligand Affinity Determination\nby Photoinduced Hyperpolarized NMR","volume":"146","author":"Bu\u0308tikofer","year":"2024","journal-title":"J. Am. Chem.\nSoc."},{"issue":"5","key":"2026072715450560000_cit67","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1021\/acs.jmedchem.3c02222","article-title":"A Novel NMR-Based Protocol to Screen Ultralow Molecular\nWeight Fragments","volume":"67","author":"Favaro","year":"2024","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026072715450560000_cit68","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41589-024-01609-1","article-title":"Chemical screening\nby time-resolved X-ray scattering to discover allosteric probes","volume":"20","author":"Brosey","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"2026072715450560000_cit69","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/17460441.2024.2354287","article-title":"Using DNA-encoded libraries\nof fragments for hit discovery of challenging therapeutic targets","volume":"19","author":"Zhao","year":"2024","journal-title":"Expert Opin. Drug Discovery"},{"issue":"4","key":"2026072715450560000_cit70","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41557-024-01442-y","article-title":"Protein-templated\nligand discovery via the selection\nof DNA-encoded dynamic libraries","volume":"16","author":"Zhou","year":"2024","journal-title":"Nat. Chem."},{"issue":"2","key":"2026072715450560000_cit71","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1039\/D0CB00222D","article-title":"Fragment-based covalent\nligand discovery","volume":"2","author":"Lu","year":"2021","journal-title":"RSC Chem. Biol."},{"issue":"1","key":"2026072715450560000_cit72","doi-asserted-by":"publisher","DOI":"10.1038\/s42004-024-01252-w","article-title":"Mapping protein binding sites by photoreactive\nfragment pharmacophores","volume":"7","author":"A\u0301bra\u0301nyi-Balogh","year":"2024","journal-title":"Commun. Chem."},{"issue":"12","key":"2026072715450560000_cit73","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1021\/acsptsci.4c00414","article-title":"Covalent\nFragments Acting as Tyrosine Mimics for Mutant p53-Y220C Rescue by\nNucleophilic Aromatic Substitution","volume":"7","author":"Klett","year":"2024","journal-title":"ACS Pharmacol.\nTransl. Sci."},{"issue":"16","key":"2026072715450560000_cit74","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300684","article-title":"Fluoromethylketone-Fragment\nConjugates Designed\nas Covalent Modifiers of EcDsbA are Atypical Substrates","volume":"19","author":"Doak","year":"2024","journal-title":"ChemMedChem"},{"issue":"30","key":"2026072715450560000_cit75","doi-asserted-by":"publisher","first-page":"20823","DOI":"10.1021\/jacs.4c04695","article-title":"Proteome-wide Ligand and Target Discovery by Using\nStrain-Enabled Cyclopropane Electrophiles","volume":"146","author":"Liu","year":"2024","journal-title":"J.\nAm. Chem. Soc."},{"issue":"6","key":"2026072715450560000_cit76","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1021\/acs.jmedchem.3c01661","article-title":"Covalent\nfragment screening and optimization\nidentifies the chloroacetohydrazide scaffold as inhibitors for ubiquitin\nC-terminal hydrolase L1","volume":"67","author":"Imhoff","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026072715450560000_cit77","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1021\/jacs.3c10581","article-title":"Using a Function-First \u2033Scout Fragment\u2033-Based\nApproach to Develop Allosteric Covalent Inhibitors of Conformationally\nDynamic Helicase Mechanoenzymes","volume":"146","author":"Ramsey","year":"2024","journal-title":"J. Am. Chem.\nSoc."},{"issue":"42","key":"2026072715450560000_cit78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409166121","article-title":"Identification of a cell-active chikungunya\nvirus nsP2 protease inhibitor using a covalent fragment-based screening\napproach","volume":"121","author":"Merten","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"2026072715450560000_cit79","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1021\/acs.jmedchem.3c01779","article-title":"Electrophilic MiniFrags\nrevealed unprecedented binding sites for covalent HDAC8 inhibitors","volume":"67","author":"Keeley","year":"2024","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026072715450560000_cit80","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202300612","article-title":"Extracting\nbinding energies and binding modes from biomolecular simulations of\nfragment binding to endothiapepsin","volume":"357","author":"Schmitz","year":"2024","journal-title":"Arch. Pharm."},{"issue":"17","key":"2026072715450560000_cit81","doi-asserted-by":"publisher","first-page":"6866","DOI":"10.1021\/acs.jcim.4c01150","article-title":"Molecular Dynamics-Ensemble Docking and Biophysical\nStudies for Structure-Based Identification of Non-Amino Acidic Ligands\nof DDAH-1","volume":"64","author":"Bigiotti","year":"2024","journal-title":"J. Chem. Inf. Model."},{"issue":"36","key":"2026072715450560000_cit82","doi-asserted-by":"publisher","first-page":"11976","DOI":"10.1039\/D1SC03563K","article-title":"C-H functionalisation tolerant to polar groups could\ntransform fragment-based drug discovery (FBDD)","volume":"12","author":"Chessari","year":"2021","journal-title":"Chem. Sci."},{"issue":"24","key":"2026072715450560000_cit83","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28247941","article-title":"Forward or Backward: Lessons Learned\nfrom Small Molecule Drugs Approved by FDA from 2012 to 2022","volume":"28","author":"Gu","year":"2023","journal-title":"Molecules"},{"key":"2026072715450560000_cit84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117241","article-title":"New FDA drug\napprovals for 2024: Synthesis and clinical application","volume":"285","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"2026072715450560000_cit85","doi-asserted-by":"publisher","first-page":"12453","DOI":"10.1021\/acs.jmedchem.1c00511","article-title":"Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective,\nand Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary\nAngioedema (HAE)","volume":"64","author":"Kotian","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026072715450560000_cit86","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved\nfor BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"2","key":"2026072715450560000_cit87","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor,\nachieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"issue":"6","key":"2026072715450560000_cit88","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and Pharmacological\nCharacterization of JNJ-42756493 (Erdafitinib), a Functionally Selective\nSmall-Molecule FGFR Family Inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer\nTher."},{"key":"2026072715450560000_cit89","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"Pexidartinib,\na Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant\nCell Tumor: A Systematic Review of Pre-Clinical and Clinical Development","volume":"14","author":"Benner","year":"2020","journal-title":"Drug Des., Dev. Ther."},{"issue":"1","key":"2026072715450560000_cit90","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a Covalent\nInhibitor of KRAS(G12C) (AMG 510) for the Treatment of Solid Tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"18","key":"2026072715450560000_cit91","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib\n(ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity\nof BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"issue":"22","key":"2026072715450560000_cit92","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib\nin Hormone Receptor-Positive Advanced\nBreast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"2026072715450560000_cit93","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1342179","article-title":"Cryo-electron\nmicroscopy-based drug design","volume":"11","author":"Cebi","year":"2024","journal-title":"Front. Mol. Biosci."},{"issue":"3","key":"2026072715450560000_cit94","doi-asserted-by":"publisher","DOI":"10.3390\/biom14030339","article-title":"Advances in AI for Protein Structure\nPrediction: Implications for Cancer Drug Discovery and Development","volume":"14","author":"Qiu","year":"2024","journal-title":"Biomolecules"},{"issue":"13","key":"2026072715450560000_cit95","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1021\/acs.jcim.2c00026","article-title":"AI-Based Protein Structure Prediction in Drug Discovery:\nImpacts and Challenges","volume":"62","author":"Schauperl","year":"2022","journal-title":"J. Chem. Inf. Model."},{"issue":"11","key":"2026072715450560000_cit96","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101873","article-title":"Generating Multibillion Chemical Space of Readily Accessible\nScreening Compounds","volume":"23","author":"Grygorenko","year":"2020","journal-title":"iScience"},{"issue":"1","key":"2026072715450560000_cit97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52018-2","article-title":"Fragment library screening by X-ray crystallography and binding site\nanalysis on thioredoxin glutathione reductase of Schistosoma mansoni","volume":"14","author":"de Souza Neto","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"2026072715450560000_cit98","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.str.2024.01.005","article-title":"Regulation of inositol 5-phosphatase\nactivity by the\nC2 domain of SHIP1 and SHIP2","volume":"32","author":"Bradshaw","year":"2024","journal-title":"Structure"},{"key":"2026072715450560000_cit99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116960","article-title":"Rational\nfragment-based design of compounds\ntargeting the PWWP domain of the HRP family","volume":"280","author":"Vantieghem","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"2026072715450560000_cit100","doi-asserted-by":"publisher","first-page":"12616","DOI":"10.1093\/nar\/gkae897","article-title":"Structure-based\ndiscovery of first inhibitors targeting the helicase activity of human\nPIF1","volume":"52","author":"Wever","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"2026072715450560000_cit101","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1039\/D3MD00724C","article-title":"Design,\nquality and\nvalidation of the EU-OPENSCREEN fragment library poised to a high-throughput\nscreening collection","volume":"15","author":"Jalencas","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"10","key":"2026072715450560000_cit102","doi-asserted-by":"publisher","first-page":"8141","DOI":"10.1021\/acs.jmedchem.4c00240","article-title":"Ligandability\nAssessment of IL-1\u03b2 by Integrated Hit Identification Approaches","volume":"67","author":"Vulpetti","year":"2024","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026072715450560000_cit103","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202400057","article-title":"Fragment-Based Design,\nSynthesis, and Characterization\nof Aminoisoindole-Derived Furin Inhibitors","volume":"19","author":"Lange","year":"2024","journal-title":"ChemMedChem"},{"issue":"1","key":"2026072715450560000_cit104","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1021\/acsmedchemlett.3c00403","article-title":"Discovery\nof Malarial Threonyl tRNA Synthetase Inhibitors by Screening of a\nFocused Fragment Library","volume":"15","author":"Bolsakova","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"2026072715450560000_cit105","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s41589-023-01514-z","article-title":"Enhanced\nmapping of small-molecule binding sites in cells","volume":"20","author":"Wozniak","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"8","key":"2026072715450560000_cit106","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s41589-023-01527-8","article-title":"Chemoproteomic development of SLC15A4\ninhibitors with anti-inflammatory activity","volume":"20","author":"Chiu","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"6694","key":"2026072715450560000_cit107","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk5864","article-title":"Large-scale\nchemoproteomics expedites ligand discovery and predicts ligand behavior\nin cells","volume":"384","author":"Offensperger","year":"2024","journal-title":"Science"},{"key":"2026072715450560000_cit108","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2024.1382512","article-title":"Quantum-assisted\nfragment-based\nautomated structure generator (QFASG) for small molecule design: an\nin vitro study","volume":"12","author":"Evteev","year":"2024","journal-title":"Front. Chem."},{"issue":"1","key":"2026072715450560000_cit109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49892-9","article-title":"In silico\nfragment-based discovery of CIB1-directed anti-tumor agents by FRASE-bot","volume":"15","author":"An","year":"2024","journal-title":"Nat. Commun."},{"issue":"8016","key":"2026072715450560000_cit110","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate\nstructure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"6693","key":"2026072715450560000_cit111","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl2528","article-title":"Generalized biomolecular\nmodeling and design with RoseTTAFold All-Atom","volume":"384","author":"Krishna","year":"2024","journal-title":"Science"},{"key":"2026072715450560000_cit112","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.str.2025.05.014","article-title":"High throughput cryo-EM\nprovides structural understanding for modulators of the lysosomal\nion channel TRPML1","volume":"33","author":"Reeks","year":"2025","journal-title":"Structure"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c02894","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/23\/24830\/66288428\/acs.jmedchem.5c02894.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/23\/24830\/66288428\/acs.jmedchem.5c02894.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:58:46Z","timestamp":1785182326000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/23\/24830\/5234451\/Fragment-to-Lead-Medicinal-Chemistry-Publications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":112,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,11,25]]},"published-print":{"date-parts":[[2025,12,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02894","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02894.s001","asserted-by":"subject"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}